If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
860
results.
Updated on
15/11/2026 [07:11:00]
Results 275 to 300 of 860
Absstract of: US20260286363A1
0000 The present disclosure provides compositions and methods of identifying, making, and using the same for the prevention and treatment of lysosomal storage diseases. Provided are also compositions and methods of diagnosing lysosomal storage diseases.
Absstract of: WO2026198531A2
The present disclosure provides a method for identifying a tumor specific small peptide that binds specifically to a CDR of an anti-tumor reactive T cell receptor (TCR) isolated from effective anti-tumor T cells and for identifying small peptides that bind specifically to the TCR. It further provides a tumor vaccine comprising an immunogenic amount of the identified tumor-specific neoantigen and formulations comprising a population of lipid nanoparticles (LNP) comprising a nucleic acid payload that encodes the tumor-specific antigen.
Absstract of: WO2026196014A1
The invention relates to a method for refined stage classification of a hereditary, preferably monogenic, neurodegenerative diseases mediated by an impairment of a disease-mediating gene, in disease-affected subjects. The invention also relates to diagnosis of a patient with the neurodegenerative diseases comprising classifying said patient in a stage of said disease. The subgroups react differently to treatment. In summary, the present inventors used a preclinical induced neuronal model to predict drug effectiveness in clinical trials, and have found a new dimension on prescreening patients before entering in clinical trials, thereby reducing the trial's failure.
Absstract of: US20260287593A1
The present invention provides methods and systems for antibody-independent spatial proteomics analysis using wavelength-specific click chemistry. Photoactivatable click chemistry reagents responsive to distinct wavelengths (UV, blue, green, red) are introduced into biological samples and selectively activated using laser matrix systems with submicron spatial control. Wavelength-specific activation enables simultaneous labeling of proteins at multiple subcellular locations or tissue regions, followed by mass spectrometry analysis to determine spatial protein distributions with subcellular resolution. The technology eliminates antibody dependencies while providing comprehensive proteome coverage (1000+ proteins per spatial region) at significantly reduced cost and time compared to conventional methods. Applications include clinical cancer diagnostics, drug discovery screening, and research applications across diverse biological systems including cell cultures, tissue sections, and FFPE clinical specimens.
Absstract of: US20260285900A1
Disclosed herein are methods of oxidizing a guanidine group comprising contacting a compound or peptide having a guanidine group with a 9,10-phenanthrenequinone or derivative providing compound with an aldehyde group in place of the guanidine group. In certain embodiments, the guanidine group is an arginine amino acid within a protein. In certain embodiments, this disclosure relates to compositions comprising 9,10-phenanthrenequinone derivatives as provided herein.
Absstract of: WO2026198565A1
A method and related system for immunodiagnostic assessment of an antigen in a sample. A sample is mixed in a sample tube (i.e., cartridge) with magnetic beads and first visualization reagent which are both conjugated with antibodies for the antigen and, if the sample includes the antigen, forms magnetic immunocomplexes. The sample tube is attached to a base having a visualization chamber, the sample is flowed into the base from the sample tube, and the magnetic beads and, if formed, the magnetic immunocomplexes are advanced into the visualization window. A second visualization reagent adapted to react with the first visualization reagent to produce a visible change is introduced. An image is acquired of the visualization window with a smartphone to assess whether the visible change has occurred. The image of the visualization window acquired using the smartphone is evaluated to assess whether the antigen is present in the sample.
Absstract of: US20260287589A1
0000 Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.
Absstract of: WO2026193586A1
Disclosed herein are methods of detecting at least two biomarkers in a DNA sample from a subject, the method comprising simultaneously, in a single test, amplifying the regions of DNA containing each of the at least two types of biomarkers in the DNA sample to produce amplified DNA; sequencing, by a sequencer, the amplified DNA to produce a sequencing read; and wherein the sequencing read identifies a presence and/or an absence of the at least two types of biomarkers, optionally, outputting a report indicating the presence or absence of the at least two types biomarkers in the DNA sample wherein the at least two types of biomarkers are selected from: (i) single nucleotide variations (SNVs), and/or insertion or deletion (indel) mutations; (ii) chromosomal copy number variations (CNVs), and (iii) gene CNVs.
Absstract of: WO2026198475A1
The present invention relates to an antigen-binding molecule specifically binding to methylpseudouridine or 1-methyluracil, a polynucleotide encoding it, a conjugate comprising it, and a method for producing such an antigen-binding molecule. The invention further relates to a method for detecting methylpseudouridine or 1-methyluracil, a method for detecting and/or quantifying a level of methylpseudouridine and/or 1-methyluracil, a kit for detecting presence and/or for quantifying a level of methylpseudouridine and/or 1-methyluracil, and a kit for enriching or purifying methylpseudouridine or polynucleotides containing methylpseudouridine.
Absstract of: US20260287601A1
A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.
Absstract of: US20260287600A1
0000 Methods, reagents, kits and systems for analyzing different proteoforms of proteins of interest are provided. The provided methods, systems, etc. provide detection, characterization and quantitation of proteoforms for different biologically relevant proteins for monitoring and characterizing biological processes.
Absstract of: US20260287596A1
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the invention relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a dataset comprising biomarker concentrations, wherein the dataset is from a sample obtained from a pediatric patient having at least one indication of septic shock, then determining whether the biomarker concentrations of each of the at least one biomarkers are greater than one or more pre-determined cut-off biomarker concentration, wherein the level of said biomarker correlates with a predicted outcome.
Absstract of: US20260287578A1
The anatomical model of a nasal cavity, such as a human nasal cavity, for in-vitro inhalation studies such as toxicological screening, intranasal drug delivery studies, and neurophysiological studies. The model includes a model body including separable upper and lower model portions together defining the nasal cavity and including fluidic channels therein that define an olfactory region of the upper model portion, and a nasal passage defined in the lower model portion. A biocompatible porous membrane is positioned between the upper and lower model portions, and the biocompatible membrane is configured for culturing olfactory epithelium cells thereon. An artificial mucous layer coats a surface of the nasal cavity and is configured to collect particles passing through the nasal cavity.
Absstract of: US20260287576A1
0000 The invention provides, in some embodiments, a potency assay matrix for assessing potency of dopaminergic neuronal progenitor cells (DANPCs) that are intended for use in treating a neurodegenerative disease such as Parkinson's Disease. The potency assay matrix can include a bioassay for L-DOPA decarboxylase (DDC) activity. In addition to the DDC activity assay matrix, the potency assay matrix may also include one or more additional mechanism of action-based assays such as bioinformatics-based assays for determining whether the DANPCs are dopaminergic neuronal progenitor cells, for determining whether the DANPCs are likely to engraft when implanted into a subject brain, and for determining whether neuronal cells that are derived from the DANPCs are likely to produce dopamine after implantation.
Absstract of: CN122794000A
本发明属于生物技术领域，具体涉及一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用。本发明一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用，诊断产品是以所述多肽或其特异性结合分子为靶分子的检测试剂盒、抗体芯片、抗体探针或检测仪。本发明克服了现有CSF‑TRUST敏感性低、常规指标特异性差的技术问题，且这种多肽标志物能够准确区分神经梅毒患者与非神经梅毒。
Absstract of: CN122790090A
0001 本发明涉及生物技术领域，具体涉及抗BD‑Tau蛋白单克隆抗体或其抗原结合片段及其应用。本发明提供的抗体对BD‑Tau蛋白具有高亲和力，能够特异性识别和结合BD‑Tau蛋白，可用于制备BD‑Tau检测试剂或试剂盒，在阿尔茨海默病的早期筛查和诊断中具有重要的应用价值。
Absstract of: CN122790086A
0001 本发明公开了一种检测tau蛋白的抗体及其应用，涉及抗体领域。本发明公开的检测tau蛋白的抗体包括重链互补决定区和轻链互补决定区，该抗体为tau蛋白的检测提供了重要的原料来源，基于该抗体的检测，灵敏度高、特异性强，有助于阿尔茨海默病等相关疾病的预测、诊断、动态监测及预后评估，具有非常高的临床应用价值。
Absstract of: AU2025211997A1
Provided are an anti-albumin antibody or an antigen-binding fragment thereof and the use thereof, and an anti-albumin nanobody with improved affinity or an antigen-binding fragment thereof. The anti-albumin antibodies or antigen-binding fragments thereof can bind to albumins from different species with high affinity. In addition, the anti-albumin antibody can be linked to a bioactive effector molecule to form a fusion construct without affecting the activity of the bioactive effector molecule.
Absstract of: US2019227064A1
0001 The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Absstract of: KR20260138113A
본 발명은 단백질의 초기 응집 거동을 관찰할 수 있는 단백질의 응집 거동 관찰 장치 및 이를 이용한 단백질의 응집 거동 관찰 방법에 관한 것이다.
Absstract of: AU2024398768A1
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Absstract of: WO2025144847A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Absstract of: CN122772976A
0001 本发明涉及生物医药技术领域，尤其是涉及基于PRDX4的PASC相关心血管系统症状风险评估应用。本发明提供了一种以PRDX4为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Absstract of: WO2025176707A1
The present invention relates to an agent that increases Nato3 expression and/or activity for use in preventing or treating a neurological disorder and related methods and uses. The present invention also relates to an expression construct or viral vector encoding an agent that increases Nato3 expression and/or activity and a host cell comprising said vector. The present invention also relates to a dopaminergic neuron or a dopaminergic progenitor comprising an expression construct encoding an agent that increases Nato3 expression and/or activity and a method of screening for a compound that improves dopaminergic function in a dopaminergic neuron.
Nº publicación: CN122775877A 18/09/2026
Applicant:
安培里翁公司
Absstract of: US2021063416A1
A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
BOPI
Electronic site
